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Abstract
A soluble form of the HIV-1 envelope glycoprotein gp160 devoid of the transmembrane anchor domain was found to bind to cholesteryl-
hemisuccinate agarose. The external subunit gp120 failed to bind to the resin, suggesting that the site responsible for the binding to
cholesterol was located in the transmembrane protein gp41.
We constructed a series of maltose binding protein (MBP) fusion proteins representing overlapping fragments of the gp41 molecule and
we studied their capacity to bind to cholesteryl beads. The domain responsible for binding to cholesterol was localised within the residues
668 to 684 immediately adjacent to the membrane spanning domain. We identified a short sequence (LWYIK, aa 678–683) comparable to
the cholesterol interaction amino acid consensus pattern published by Li and Papadopoulos [Endocrinology 139 (1998) 4991]. We
demonstrated that the sequence LWYIK synthesized fused to the MBP was able to bind to cholesteryl groups. A synthetic peptide containing
the sequence LWYIK was found to inhibit the interaction between cholesteryl beads and MBP44, an MBP fusion HIV-1 envelope protein that
contains the putative cholesterol binding domain. Human sera obtained from HIV-1 seropositive patients did not react in ELISA to the
LWYIK sequence, suggesting that this region is not exposed to the immune system. The biological significance of the interaction between
gp41 and cholesterol is discussed.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The HIV-1 envelope protein is synthesized from a
precursor gp160. During its transport to the cell surface,
a fraction of gp160 is cleaved to gp120–gp41. The
external gp120 is responsible for the attachment to the
cellular receptor and coreceptor(s), whereas the transmem-
brane protein gp41 is responsible for fusion of the viral
envelope with the plasma membrane of the target cells.
Membrane fusion requires the cleavage of the inactive
precursor gp160 and is thought to be mediated by the
hydrophobic N-terminus of gp41. Previous studies have
demonstrated a link between fusion and lipid composition
for several enveloped viruses. Roos et al. [2] have reported
that the manipulation of cellular lipid content modified the
susceptibility of cells to viral fusion. Semliki Forest Virus
has been demonstrated to require cholesterol, a major
component of mammalian cell plasma membrane for
membrane fusion and exit [3]. Studies have shown that
the fusion peptide of Semliki Forest Virus and the F1
subunit of the fusion protein of Sendai virus bind to
cholesterol [4,5]. Inhibitors of cholesterol synthesis have
been shown to inhibit the syncytia formation induced by
Measles virus [6]. Several observations suggest that the
HIV-1 envelope glycoprotein may also interact with cho-
lesterol. Membranes of HIV and HIV-infected cells are rich
in cholesterol and the cholesterol-to-phospholipid molar
ratio of HIV-1 envelope is 2.5 times that of its host cell
membrane [7]. Inhibitors of cholesterol synthesis also
inhibit cell fusion formation induced by HIV-1 [8]. Drugs
that extract cholesterol from the cellular membrane exert
an anti-HIV effect in vitro [9–11]. Recent studies suggest
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that HIV-1 uses cholesterol and sphingolipids during bud-
ding [12]. The objective of this study was to investigate
the interaction of cholesteryl groups with the HIV-1
envelope protein. We have determined that a small region
immediately adjacent to the membrane spanning domain of
gp41 was sufficient to confer interaction with cholesteryl
groups.
2. Materials and methods
2.1. Chemicals
Cholesteryl-hemisuccinate agarose (1 Amol cholesteryl
hemisuccinate per milliliter of packed gel), concanavalin A
(Con A) sepharose 4B (16 mg lectin per milliliter of packed
gel), calmodulin (CaM) agarose (1.7 mg calmodulin per
milliliter of packed gel) and cholic acid agarose (5 Amol
cholic acid per milliliter packed gel) were from Sigma.
Peptides 2032 (aa 675–685, HIV-1 MN, DITNWLWYIKI),
4767 (aa 671–690, HIV-1 89.6P, FDITNWLWYIRLFI-
MIVGGL) and 2029 (aa 641–660, HIV-1 MN, SLIYSL-
LEKSQTQQEKNEQE) were obtained from the NIH AIDS
Research and Reference Reagent Program. Peptides EVA
798.20 (aa 701–720, SIV, ILLRIVIYIV QMLAKLRQGY)
was obtained through the Medical Research Council AIDS
Reagent Project. Purified maltose binding protein (MBP)
was from New England BioLabs.
2.2. Vaccinia virus (VV) recombinants
VV recombinants, VVTG1132 expressing gp120LAI and
VVTG5156 expressing a soluble chimeric envelope glyco-
protein containing gp41LAI and gp120MN, were obtained
from Dr. M.-P. Kieny [13]. VVTG5156, which is a deriv-
ative of VVTG1163 [13] in which the HIV LAI gp120
coding sequence has been replaced by HIV-1MN counter-
part, contains an envelope gene modified by site-directed
mutagenesis to destroy the gp120–gp41 cleavage site, to
remove the transmembrane anchor domain of gp41 and to
truncate gp41 at aa 29 into the intracytoplasmic domain.
2.3. Metabolic labelling with 35S-methionine/cysteine
HeLaT4 cells (HeLa cells stably expressing CD4) were
maintained in RPMI-1640 medium supplemented with 10%
foetal bovine serum, glutamine, 10 mM HEPES and pen-
icillin/streptomycin in 25-cm3 tissue culture flasks. For
radiolabelling of HIV-1 envelope protein expressed from
VV recombinants, confluent HeLaT4 cells were infected
with VV (5 PFU/cell) and 16 h later labelled for 4 h with
35S-methionine/cysteine (TRANS 35S-LABEL, ICN Radio-
chemicals) (100 ACi/ml) in methionine/cysteine deficient
medium. The medium (2 ml) was added 30 min before the
addition of radioactivity. The supernatants that contained the
labelled secreted proteins were stored at  20 jC.
2.4. Construction of MBP fusion HIV-1 proteins
An isopropyl-beta-D-thiogalactopyranoside (IPTG) indu-
cible expression plasmid pMAL-c2E (New England BioL-
abs) was used to generate recombinant MBP fusion proteins
containing fragments of the HIV-1 envelope protein. The
foreign sequence was inserted in frame, downstream of the
Escherichia coli malE gene, which encodes MBP. The
plasmids containing the wild-type HIV-1 envelope glyco-
protein genes used to generate the constructs have been
previously described [14].
The plasmid pMBP35, which expresses the amino acid
sequence 463–619 of 92/UG/024 HIV-1 isolate, was ob-
tained by inserting SpeI (nt1365)–XbaI (nt1835) fragment
from p92/UG/024 (ARP2008) into pMAL-c2E.
The plasmid pMBP39, which expresses the amino acid
sequence 542–641 of HIV-1 LAI isolate, was obtained by
inserting a 286 bp HaeIII (nt7835)–HindIII (nt8121) frag-
ment from pNL4-3 into pMAL-c2E.
The plasmid pMBP44, which expresses the amino acid
sequence 618–684 of HIV-1 92/BR/025.9 isolate, was
obtained by inserting a 202 bp BglII (nt1824)–SspI
(nt2026) fragment from p92/BR/025.9 (ARP239-1) into
pMAL-c2E.
The plasmid pMBP42, which expresses the amino acid
sequence 668–801 of HIV-1 GB8 isolate, resulted from the
insertion of an ApoI (nt1980)–PstI (nt2381) fragment from
pGB8.C4 (ARP210) into pMAL-c2E.
The plasmids pMBP31 and pMBP45, which express the
amino acid sequences 583–856 and 752–856 of HIV-1 92/
UG/975 isolate, respectively, were obtained by inserting the
XbaI (nt1712)–PstI (nt2589) and XmnI (nt2214)–PstI
(nt2589) fragments from p92/UG/975 (ARP2007) into
pMAL-c2E, respectively.
The plasmid pMBP38, which expresses the amino acid
sequence 640–752 of HIV-1 LAI isolate, was obtained by
inserting a 344 bp HindIII (nt8121)–BamHI (nt8465) frag-
ment from pNL4-3 into pMAL-c2E.
The construct MBP-LWYIK, which includes amino acids
679–683, was obtained by introducing a synthetic DNA
fragment encoding the amino acids LWYIK followed by a
stop codon at the end of the malE gene so that eight arginine
residues separate the MBP from the peptide sequence. This
plasmid was constructed by a two-step PCR amplification
using the primers mal51 (5V-CTGTGGTATATAAAAT-
GAAACCTCGGGGATGACGATGACAAGG-3V) and
mal31 (5V-TCATTTTATATACCACAGGTTATTGT-
TATTGTTGTTGTTGTTCGAGCTCGAA-3V) for the inser
tion, and mal30 (5V-GGTAACGCCAGGGTTTTCCCA-
GTC-3V) and mal50 (5V-GCTTACCCGATCGCTGTT-
GAAGCGTTA-3V) as flanking primers. The 1-kb fragment
that was generated was purified and inserted into pMAL-c2E
by BglII–HindIII digestion.
All the inserted sequences were verified by sequencing.
The numbering of residues is based on the sequence of the
gp160 of the HIV-1 HXB2.
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2.5. Purification of MBP fusion HIV-1 proteins
Protein expression was induced by IPTG as recommen-
ded by the manufacturer. Cells were harvested by centrifu-
gation and resuspended in column buffer (10 mM Tris–HCl,
pH 7.4, 200 mMNaCl, 1 mM EDTA). Proteins were released
in the supernatant by cell sonication. After centrifugation, the
MBP fusion protein purification was done by amylose
affinity chromatography according to the manufacturer’s
protocols or by using the method published by Srinivasan
and Bell [15]. Purified MBP proteins were separated by
SDS-PAGE and detected by Western blotting and ELISA
using an anti-MBP rabbit antiserum (New England BioLabs)
and/or specific monoclonal antibodies.
2.6. Iodination of MBP44
MBP44 in column buffer was iodinated with 125I (as
Na125I Amersham) according to the protocol described by
Helmkamp et al. [16]. After labelling, MBP44 was
purified on an amylose resin column by affinity chroma-
tography.
2.7. Interaction of 35S-labelled HIV-1 glycoproteins with
resins
Supernatants containing labelled HIV-1 envelope pro-
teins were diluted in 1 ml PBS and added to the resin
(100 Al). The resin suspension was incubated 2 h at room
temperature with constant mixing. After centrifugation,
the supernatant was discarded and the pellet extensively
washed with PBS. The proteins were dissociated from the
resin by boiling for 1 min in sampling buffer (65 mM
Tris–HCl, pH 6.8, 2% SDS, 10% glycerol, 0.001%
bromophenol blue) in presence of 1% 2-mercaptoethanol.
The 35S-HIV-1 envelope proteins released from the resin
were analyzed by 7% SDS-PAGE and visualized by
autoradiography.
2.8. Interaction of MBP fusion proteins with cholesteryl-
hemisuccinate agarose
MBP fusion proteins were diluted in 1 ml PBS and
added to the resin (100 Al). The resin suspension was
processed as indicated above. After dissociation from the
resin by boiling, the proteins were analyzed by 8% SDS-
PAGE. The MBP fusion proteins were transferred onto
nitrocellulose. The membrane was blocked for 1 h with
PBS containing 5% skim milk and incubated overnight at
4 jC with rabbit anti-MBP antiserum (New England
Biolabs). After washing with PBS, bound antibody was
probed with horseradish peroxidase-conjugated goat anti-
rabbit IgG (whole molecule) (Sigma) and developed with
3,3-diaminobenzidine (DAB) peroxidase substrate (Sigma
Fast) or processed with the ECL Western Blotting Kit
(Amersham).
2.9. ELISA methods
For peptide ELISA, microtiter plates were coated with
peptides 2032 or 4767 (0.5 Ag/well) in 0.1 M sodium
carbonate buffer (pH 9.6) overnight at 4 jC. The plates were
washed with TBS (144 mM NaCl, 25 mM Tris–HCl, pH
7.5) containing 0.5% Tween 20 and blocked with the same
buffer plus 2% BSA for 1 h at 37 jC. After washing, 100 Al
of serum (diluted 1:50 in TBS) (obtained from the University
Hospital of Saint-Etienne and from the University Hospital
of Lyon) were added to the wells and incubated overnight at
4 jC. After washing, the detection was done by using
successively horseradish peroxidase-conjugated goat anti-
human IgG and o-phenylenediamine dihydrochloride (OPD)
substrate (Sigma). The measurement of absorbance was read
at 492 nm. The cutoff value was defined as the mean value of
absorption of negative control samples plus 2 S.D.
For MBP-LWYIK ELISA, microtiter plates were coated
with 150 Al 0.5% dextrin in TBS overnight at 4 jC. The
plates were washed with TBS containing 0.5% Tween 20
and blocked with the same buffer plus 2% BSA for 1 h at 37
jC. Sonicated bacterial extract containing MBP-LWYIK
was centrifuged and 100 Al of the supernatant (500 Ag
protein/ml) was added to the wells for 3 h at 37 jC. After
washing, 100 Al of serum (diluted 1:50) was added to the
wells and incubated overnight at 4 jC. The detection
procedure was the same as that described above.
3. Results
3.1. Interaction of 35S-HIV-1 envelope glycoproteins with
cholesteryl-hemisuccinate agarose
To examine the putative interaction of the HIV-1-enve-
lope with cholesterol, we studied the retention of the env
protein metabolically labelled with TRAN 35S on choles-
teryl-hemisuccinate agarose. Con A sepharose 4B and CaM
agarose were used as positive controls. Previous studies have
demonstrated that Con A, a mannose-specific lectin, inter-
acts strongly with gp120 and that CaM, a EF-hand protein,
binds with high affinity to the cytoplasmic tail of the gp41
[17–19]. The cells were infected with recombinant vaccinia
virus VVTG5156, which expresses a soluble and uncleaved
form of HIV-1 gp160 devoid of the membrane spanning
domain. The cells were labelled with 35S-methionine/cys-
teine as described in Materials and methods. Equal fractions
of the supernatant containing secreted 35S-gp1605156 were
incubated in the presence of the resins. As shown in Fig. 1A,
the 35S-gp1605156 bound to cholesteryl-hemisuccinate agar-
ose with the same affinity as to CaM agarose and Con A
sepharose 4B. The 35S-gp1605156 bound with a much lower
affinity to heparin agarose and to the hydrophobic resin
cholic agarose even if cholic acid and cholesterol are
structurally close. Heparin, a highly charged anionic glyco-
sylaminoglycan, is known to inhibit the HIV-1-induced cell
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fusion by electrostatic interaction with the gp120 subunit
[20]. In Fig. 1B, the samples have been analyzed under
nonreducing conditions. We observed that monomeric and
dimeric forms of 35S-gp1605156 interacted with cholesteryl-
beads. To show the position of 35S-gp1605156, an aliquot of
the supernatant of vaccinia-infected cells was immunopreci-
pitated with anti-gp41 MAb 27 and Sepharose-protein A
(Fig. 1A, lane 6; B, lane 3). To determine if the cholesterol
binding domain was in the gp120 subunit, 35S-labelled
gp120 (secreted from cells infected with VVTG1132
recombinant) was incubated with resins. Con A-derivatized
resin was used as a positive control and CaM agarose as a
negative control. There is no CaM-binding domain in gp120
subunit [19]. 35S-gp120HIV-1 LAI bound with a high
affinity to Con A derivatized resin but not to the choles-
teryl-hemisuccinate and CaM derivatized resins (not shown).
3.2. Interaction of MBP-fusion proteins representing
regions of gp41 with cholesteryl-hemisuccinate agarose
To characterise the region of gp41 which binds to choles-
terol, we used a series of recombinant proteins that represent
the whole gp41 molecule. Envelope gene fragments were
ligated into the pMAL-c2E plasmid and expressed in E. coli.
Sonicated bacterial extracts containing HIV-1 recombinant
MBP protein were centrifuged and an aliquot of each super-
natant was incubated with immobilized cholesterol. The
complexes were washed in PBS, denatured in sampling
buffer and then an aliquot of each supernatant was analyzed
by SDS-PAGE. The MBP protein was detected by Western
blotting with an anti-MBP antiserum and DAB substrate. As
shown in Fig. 2, the construct MBP35 (aa 463–619), which
contains the fusogenic sequence of gp41, the construct
MBP45 (aa 752–856) which contains a fragment of the
cytosolic domain of gp41, and the construct MBP39 (aa
542–641) which contains an immunodominant epitope of
gp41 failed to bind to cholesteryl groups. The constructs
MBP42 (aa 668–801), MBP38 (aa 640–752) and MBP31
(aa 583–856) interacted with immobilized cholesterol. In the
experiment illustrated by Fig. 3, increasing concentrations of
purified MBP44 (aa 618–684) (panel A) and MBP38 (panel
B) were incubated with the same amount of cholesteryl-
beads. Proteins were transferred to nitrocellulose, probed
with an anti-MBP antiserum and visualized with the ECL
detection system.
Purified MBP (43 K) was used as a molecular weight
marker and to evaluate the detection system (Fig. 3A, lanes 1
and 2; B, lane 1; C, lanes 1 and 2). Purified MBP did not bind
to cholesteryl beads (not shown). MBP44 exhibited mono-
meric and dimeric forms and both forms interacted with
cholesteryl-beads. We observed that comparable amounts of
MBP44 and MBP38 interacted with cholesteryl-agarose. To
determine the region of gp41 involved in cholesterol binding
recombinant envelope protein sequences were aligned (Fig.
4). Cholesteryl groups bound to a region spanned by the
constructs MBP44 and MBP42. MBP44 and MBP42 overlap
by 17 amino acids.
Fig. 2. Interaction of sonicated bacterial extract containing MBP fusion
proteins representing fragments of HIV-1 envelope protein with cholesteryl-
hemisuccinate agarose. Clarified sonicated bacterial extract (300 Al)
containing MBP42 (lane 2), MBP45 (lane 3), MBP38 (lane 4), MBP35
(lane 5), MBP31 (lane 6) and MBP39 (lane 7) were incubated with
cholesteryl-hemisuccinate agarose (100 Al). The proteins were released
from the beads and analyzed by SDS-PAGE as indicated in Materials and
methods. After Western blotting, the membranes were incubated in the
presence of a rabbit anti-MBP antiserum. Bound antibodies were revealed
with an anti-rabbit IgG peroxidase conjugate and DAB peroxidase
substrate. Lane 1 shows purified MBP obtained from New England
BioLabs (100 ng). The lane M contains molecular weight markers.
Fig. 1. Interaction of 35S-recombinant HIV-1 envelope glycoprotein with
cholesteryl-hemisuccinate agarose. (A) Interaction of 35S-gp1605156 with
resins: lane 1, CaM-agarose; lane 2, cholic acid agarose; lane 3, cholesteryl-
hemisuccinate agarose; lane 4, Con A-sepharose 4B; lane 5, heparin-
agarose. Lane 6 shows 35S-gp1605156 immunoprecipitated with MAb 27
and adsorbed onto Sepharose-protein A. The samples were run on 7% SDS-
PAGE under reducing conditions. The positions of the radiolabelled
molecular weight markers are shown on the right. (B) Interaction of 35S-
gp1605156 with resins: lane 1, cholic acid agarose; lane 2, cholesteryl-
hemisuccinate agarose. Lane 3 shows 35S-gp1605156 immunoprecipitated
with MAb 27 and adsorbed onto Sepharose-protein A. The samples were
run on 7% SDS-PAGE under nonreducing conditions.
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3.3. Interaction of MBP-fusion protein representing the
sequence LWYIK of gp41 with cholesteryl-hemisuccinate
agarose
To more closely characterise the location of the choles-
terol binding site, we looked in the sequence 668–684 of
HIV-1 envelope glycoprotein for the presence of the cho-
lesterol recognition/interaction amino acid consensus pat-
tern identified by Li and Papadopoulos [1]. These authors
described a consensus pattern for proteins that bind choles-
terol as -L/V-(X)1–5-Y-(X)1–5-R/K-. This pattern was found
in the sequences LWYIK or LWYIR immediately adjacent
to the membrane-spanning domain of gp41. To investigate
whether the binding was dependent on amino acids
LWYIK, a construct expressing the motif LWYIK was
realised by PCR. Increasing concentrations of purified
MBP-LWYIK were incubated with the same amount of
cholesteryl-beads. Proteins were transferred to nitrocellu-
lose, probed with an anti-MBP antiserum and visualized
with the ECL detection system. As shown in Fig. 3C, MBP-
LWYIK interacted with immobilized cholesterol. By West-
ern blotting and detection with an anti-MBP antiserum and
DAB substrate, we estimated that approximately 700 ng of
MBP-LWYIK were able to bind to 100 Al of packed gel
(not shown).
3.4. Effects of synthetic peptides on the interaction 125I-
MBP44/cholesteryl-beads
We investigated the effects of the following peptides
on the interaction between 125I-MBP44 and cholesteryl-
beads: 2032 representing the region that immediately
precedes the transmembrane anchor and contains the
Fig. 4. Amino acid alignment of MBP constructs interacting with cholesteryl-hemisuccinate agarose. Shared sequences between these proteins are indicated.
Fig. 5. Inhibition of the interaction between 125I-MBP44 and cholesteryl-
hemisuccinate agarose by synthetic peptide 2032. Purified 125I-MBP44 was
incubated in the presence (lane 2) or absence (lane 3) of peptide 2032.
Peptide 2032 (10 Ag) was diluted in 1 ml PBS and incubated for 2 h with
cholesteryl-hemisuccinate agarose (100 Al). 125I-MBP44 (700 ng) was
added to the resin suspension and then the mixture was incubated for a
further 2 h. The proteins were released from the beads and analyzed by
SDS-PAGE as described in Materials and methods. The gel was dried and
exposed to Bio Max Light-1 film (Kodak). Lane 1 shows an aliquot of
purified 125I-MBP44 prior to interaction with the resin. The migration
positions of molecular weight markers are indicated.
Fig. 3. Interaction of purified MBP-recombinant HIV-1 envelope proteins
with cholesteryl-hemisuccinate agarose. (A) Interaction of 25 ng (lane 3),
50 ng (lane 4), 75 ng (lane 5) and 125 ng (lane 6) of MBP44 with resin (50
Al). The same aliquots of sample (25 Al) were loaded in each well. Lanes 1
and 2 show 10 and 5 ng of purified MBP from New England BioLabs,
respectively. (B) Interaction of 25 ng (lane 2), 50 ng (lane 3), 75 ng (lane 4),
100 ng (lane 5) and 125 ng (lane 6) of MBP38 with resin (50 Al). The same
aliquots of sample (25 Al) were loaded in each well. Lane 1 shows purified
MBP from New England BioLabs (20 ng). (C) Interaction of 200 ng (lane
3), 400 ng (lane 4), 600 ng (lane 5) and 900 ng (lane 6) of MBP-LWYIK
with resin (100 Al). The same aliquots of sample (10 Al) were loaded in each
well. Lanes 1 and 2 show 5 and 10 ng of purified MBP from New England
BioLabs, respectively. Lane 7 shows an aliquot of purified MBP-LWYIK
prior to interaction with the resin. In A, B and C, the samples were run on
8% SDS-PAGE under reducing conditions. After Western blotting, the
proteins were visualized with the ECL detection system. The signal strength
was estimated after 15–20 s exposure.
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LWYIK sequence, EVA 798.20 representing the trans-
membrane anchor of SIV, and 2029 representing a frag-
ment of MBP44. Cholesteryl beads were incubated in the
presence of peptide and 125I-MBP44.
As shown in Fig. 5, the interaction between cholesteryl
beads and MBP44 was inhibited by peptide 2032. Synthetic
peptides EVA 798.20 and 2029 did not inhibit the inter-
action between 125I-MBP44 and cholesteryl beads (not
shown).
3.5. Comparison of the cholesterol binding site LWYIK of
the HIV-1 envelope protein with homologous regions of
other retroviruses
As shown in Fig. 6, the HIV-1 envelope sequence
LWYIK is highly conserved among HIV-1 isolates. The
sequence contains three hydrophobic amino acids (L, W,
I). The lysine residue (K), a positively charged amino
acid, adjacent to the membrane-spanning domain can be
replaced by arginine (R), another positively charged
amino acid. The conserved lysine residue is separated
from two aromatic residues, tryptophane (W) and tyrosine
(Y) by an isoleucine residue (I). The sequence LWYIK is
also found in the SIVcpzant strain envelope protein. For
most of the SIV and HIV-2 strains, the putative motif
responsible for binding to cholesterol consists of 6 amino
acids. The pattern is L(AS/TS)WI(K/R) and is slightly
different from that described for HIV-1. However, the
sequence is also characterised by a positively charged
amino acid (K/R) adjacent to the membrane spanning
region and separated from an aromatic amino acid by the
hydrophobic residue isoleucine.
3.6. Reactivity of sera of HIV-1 seropositive subjects to
MBP-LWYIK
The reactivity of 27 sera collected from HIV-1 sero-
positive persons to MBP-LWYIK or to the peptides
representing that region was determined by ELISA as
described in Materials and methods. Ten sera collected
from HIV-1 seronegative healthy persons were tested in
parallel. None of the 27 sera tested was found to react with
the sequence LWYIK or LWYIR (not shown).
4. Discussion
The studies described here provide evidence that HIV-1
gp160 binds to cholesteryl groups. The envelope protein
binds to cholesteryl groups to a similar extent as that
obtained with CaM- and Con A-derivatized resins. Con A-
derivatized resins are usually used to purify gp120 molecules
by affinity chromatography. The constructs MBP35,
MBP39, MBP44, MBP42 and MBP45 contain hydrophobic
domains [21,22]. Only MBP44 and MBP42 were found to
bind to cholesteryl beads. This indicates that the interaction
between MBP44 or MBP42 and cholesteryl groups cannot
be explained simply by an interaction between a hydro-
phobic domain and a lipophilic compound.
We localised a cholesterol binding domain (sequence
LWYIK) within the region immediately adjacent to the
membrane-spanning domain of gp41. The sequence LWYIK
has been found by comparison with the cholesterol recog-
nition/interaction amino acid consensus pattern identified by
Li and Papadopoulos [1] as -L/V-(X)1–5-Y-(X)1–5-R/K-.
These authors have identified a cholesterol recognition
amino acid motif on the carboxy-terminus of peripheral-
type benzodiazepine receptor. This motif was common to
various proteins known to interact with cholesterol [1]. In
addition, they have demonstrated that replacement of Y by S
or R by L completely abolished the ability of peripheral-
type benzodiazepine receptor to take up cholesterol [1].
Previous studies have demonstrated that a stretch of 17
hydrophobic and uncharged amino acids immediately adja-
cent to the border of the membrane spanning domain of
gp41 is required for envelope-mediated membrane fusion
[23]. Helseth et al. [24] have demonstrated that a mutant
with a change in the sequence LWYIK (replacement of the
positively charged amino acid lysine by the nonpolar
residue isoleucine) was defective for syncytium formation
and replication even though the level of envelope glyco-
protein on the cell or virion surface was comparable to that
of the wild-type protein. Salzwedel et al. [23] found similar
results by replacement of K with the sequence NSG (aspar-
agine–serine–glycine) or with the nine membrane-primal
residues of human erythrocyte decay-accelerating factor
(DAF). Salzwedel et al. [23] also demonstrated that the
deletion of LWYI had a significant effect on syncytium
formation. These observations suggest strongly that inter-
Fig. 6. Comparison of the conserved tryptophan-rich motif in the
membrane-proximal region of gp41 with homologous regions of other
retroviruses. The putative cholesterol binding sites are underlined.
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action of LWYIK with cholesterol is involved in the fusion
process. The fact that comparable amounts of MBP44 and
MBP38 interact with cholesteryl-hemisuccinate-agarose
suggests that the transmembrane region has a minor role
in the binding to cholesterol. In agreement with this, we
showed that the soluble and uncleaved form of the envelope
protein gp160 deleted from the transmembrane region was
able to bind cholesterol-derivatized resin agarose.
Asano and Asano [5] demonstrated that the hydrophobic
side chain and the polar 3VOH-group of cholesterol were not
involved in the binding of the Sendai virus fusion protein
with cholesterol. They postulated that the cholesterol binding
to the fusion protein of Sendai virus was dependant of the
cholesterol nucleus. In our studies, the polar hydroxyl group
of cholesterol is esterified, suggesting a similar mechanism.
Similarities were found when the region immediately
adjacent to the border of the membrane spanning domain of
HIV-1 gp41 was compared to the envelope proteins of other
retroviruses: the number of hydrophobic residues, the pres-
ence of a positively charged amino acid (K/R) adjacent to
the membrane spanning region and separated from benzenic
amino acid(s) by an isoleucine residue. This suggests that
residues with aromatic ring and positively charged amino
acid are particularly important in the motif.
In many of the SIV sequences, the Y residue, an aromatic
amino acid, found in the putative cholesterol binding motif
described by Li and Papadopoulos is replaced by W, another
aromatic amino acid. In addition, Y and W belong to the
same group of amino acids when classified by the chemical
characteristics of their side groups (neutral–polar).
Sera collected from HIV-1 seropositive persons did not
react with the sequence LWYIK, suggesting that the region
adjacent to the membrane-spanning domain, hydrophobic, is
poorly immunogenic or not exposed to the immune system.
The incorporation of HIV-1 envelope glycoproteins into
liposomes has been demonstrated to preserve the native
trimeric structure of the glycoprotein [25]. The presence of
cholesterol in the liposomal solution may explain the capacity
of liposomes to stabilize the HIV-1 envelope glycoproteins.
Cholesterol, sphingolipids and glycolipids are involved in
the formation of cellular raft domains. Recent reports suggest
that HIV-1 may use lipid rafts during budding [12]. The
interaction of cholesterol with gp41 may be critical for
localization of the HIV-1 envelope glycoprotein to lipid rafts.
Finally, it is probable that the interaction between cho-
lesterol and the region immediately adjacent to the mem-
brane spanning domain plays a major role in the fusion
process. However, further studies are necessary to determine
if that interaction is involved in other steps of the virus life
cycle.
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